DuPont makes an­oth­er for­ay in­to drug R&D, throw­ing its name in­to the mi­cro­bio­me hat

Hav­ing spent the past three years get­ting up to speed with all the in­no­va­tions around the hu­man mi­cro­bio­me, DuPont Nu­tri­tion & Bio­sciences — the food, health and phar­ma fo­cused unit of the slimmed-down con­glom­er­ate — is div­ing in­to the ther­a­peu­tic space.

The Copen­hagen-based op­er­a­tion — whose cor­po­rate slo­gan is “the mir­a­cles of sci­ence” — said it’s team­ing up with MRM Health, a Bel­gian up­start mi­cro­bio­me spe­cial­ty play­er spun out of Ghent Uni­ver­si­ty spin­off ProDi­gest, to ad­vance new treat­ments for meta­bol­ic dis­eases. It’s al­so in­vest­ing in MRM’s €14m round, which is de­signed to fund clin­i­cal stud­ies of a lead pro­gram in in­flam­ma­to­ry bow­el dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER